It has been nearly 14 years since David Maršálek happened to meet Professor Dušan Miljković in the USA – the man who first introduced a hydrogen-based dietary supplement to the world. This moment set in motion a journey that has led to a project with global ambitions today.
Over time, other top scientists joined him – Professor Shigeo Ohta from Japan, Professor Jan Slezák, a team from Palacký University, and other experts from Europe, the USA, and Japan. This is how H2 Global Group was created, followed later by H2 Medical Technologies, focused on research and development of molecular hydrogen in medicine.
From a single idea to a breakthrough clinical study
What began as an interest in dietary supplements gradually revealed that molecular hydrogen has potential in medicine as well – especially in the field of neurodegenerative diseases. Thanks to an international team of experts, the idea emerged to create the world’s first medical device based on molecular hydrogen.
And in 2025, a major breakthrough came:
-
SÚKL approved the first clinical study in the Czech Republic evaluating the safety of inhaling molecular hydrogen in patients with mild cognitive impairment.
-
The study builds on successful Japanese research by Professor Ohta, who is also behind the European patent EP3701956B1 for the prevention and treatment of dementias.
A Czech project with global reach
We collaborate on this project with leading scientific teams, including Professor MUDr. David Školoudík and experts from Palacký University. Our vision is to contribute to the medicine of the future—one that focuses not only on treatment, but above all on the prevention of civilization diseases.
Although we are a small country, today we have something exceptional:
patents, technology, and an international team capable of setting the direction for global medicine.
The full article titled:
A Czech Breakthrough in Global Medicine: Molecular Hydrogen Becomes the Subject of the First Clinical Study of Its Kind in the Czech Republic